Synapse - Anthony Mato

Search Within

Anthony R Mato

Results (236)

Real-world outcomes with first-line ibrutinib (Ibr) versus chemoimmunotherapy (CIT) in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Final analysis results from the InformCLL registry

Meeting Abstract

Ghosh, N.; Sharman, J. P.; Barrientos, J. C.; Brander, D.; Gutierrez, M.; Wu, L.; Qureshi, Z. P.; Upasani, S.; Naganuma, M.; Mato, A. R.
Blood (2022)

Fulltext@MSK | Save

Real world comparison of bruton tyrosine kinase inhibitors and venetoclax in patients diagnosed with chronic lymphocytic leukemia or small lymphocytic lymphoma

Meeting Abstract

Roeker, L. E.; Han, Y.; Ryan, K. J.; Teschemaker, A.; Mato, A. R.
Blood (2022)

Fulltext@MSK | Save

Initiating first-line (1L) Ibrutinib (Ibr) in patients (pts) with chronic lymphocytic leukemia (CLL) improves overall survival (OS) outcomes to rates approximating an age-matched population of ≥65 years

Meeting Abstract

Ghia, P.; Owen, C.; Barrientos, J. C.; Barr, P. M.; Mato, A. R.; Shi, C. X.; Szoke, A.; Abbazio, C.; Krigsfeld, G. S.; Burger, J. A.
Blood (2022)

Fulltext@MSK | Save

Comparing acalabrutinib and ibrutinib in the real world: A study of 2,509 patients with chronic lymphocytic leukemia

Meeting Abstract

Roeker, L. E.; DerSarkissian, M.; Ryan, K. J.; Chen, Y.; Wahlstrom, S. K.; Hakre, S.; Yu, L.; Guo, H.; Mato, A. R.
Blood (2022)

Fulltext@MSK | Save

Safety and tolerability of pirtobrutinib monotherapy in patients with B-cell malignancies who were previously intolerant to a covalent BTK inhibitor: Results from the phase 1/2 BRUIN study

Meeting Abstract

Shah, N. N.; Wang, M. L.; Brown, J. R.; Patel, K.; Woyach, J. A.; Wierda, W. G.; Ujjani, C. S.; Eyre, T. A.; Zinzani, P. L.; Alencar, A. J.; more...
Blood (2022)

Fulltext@MSK | Save

Efficacy of pirtobrutinib in covalent BTK-inhibitor pre-treated relapsed/refractory CLL/SLL: Additional patients and extended follow-up from the phase 1/2 BRUIN study

Meeting Abstract

Mato, A. R.; Woyach, J. A.; Brown, J. R.; Ghia, P.; Patel, K.; Eyre, T. A.; Munir, T.; Lech-Maranda, E.; Lamanna, N.; Tam, C. S.; more...
Blood (2022)

Fulltext@MSK | Save

NX-2127-001, first-in-human trial of NX-2127, a Bruton's tyrosine kinase-targeted protein degrader, in patients with relapsed or refractory chronic lymphocytic leukemia and B-cell malignancies

Meeting Abstract

Mato, A. R.; Wierda, W. G.; Ai, W. Z.; Flinn, I. W.; Tees, M.; Patel, M. R.; Patel, K.; O'Brien, S.; Bond, D. A.; Roeker, L. E.; more...
Blood (2022)

Fulltext@MSK | Save

Kinase dead BTK mutations confer resistance to covalent and noncovalent BTK inhibitors but are susceptible to clinical stage BTK degraders

Meeting Abstract

Montoya, S.; Bourcier, J.; Thompson, M. C.; Noviski, M.; Tan, M.; Wang, E.; Mi, X.; Brathaban, N.; Risso, C. B.; Tsai, D.; more...
Blood (2022)

Fulltext@MSK | Save

Efficacy of pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in relapsed / refractory Waldenström macroglobulinemia: Results from the phase 1/2 BRUIN study

Meeting Abstract

Palomba, M. L.; Patel, M. R.; Eyre, T. A.; Jurczak, W.; Lewis, D. J.; Gastinne, T.; Ma, S.; Cohen, J. B.; Patel, K.; Brown, J. R.; more...
Blood (2022)

Fulltext@MSK | Save

Efficacy of pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in Richter transformation: Results from the phase 1/2 BRUIN study

Meeting Abstract

Wierda, W. G.; Lewis, D. J.; Ghia, P.; Shah, N. N.; Coombs, C. C.; Cheah, C. Y.; Lamanna, N.; Rhodes, J. M.; Hoffmann, M.; Ma, S.; more...
Blood (2022)

Fulltext@MSK | Save